|EX-99.1 - PRESS RELEASE - HeartWare International, Inc.||d349850dex991.htm|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of report (date of earliest event reported): May 8, 2012
HEARTWARE INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of
205 Newbury Street, Suite 101
Framingham, MA 01701
(Address of principal executive offices)
Registrants telephone number, including area code: 508.739.0950
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 8.01 Other Events
On May 8, 2012, we announced that enrollment is complete in ENDURANCE, the Companys pivotal Destination Therapy clinical study to evaluate the use of the HeartWare® Ventricular Assist System in patients with end-stage heart failure. The Company also noted the achievement of over 2,000 HVAD implants on a global basis.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
Exhibit 99.1 HeartWare International, Inc. press release dated May 8, 2012.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|HeartWare International, Inc.|
|Date: May 9, 2012||By:|
|Name: Lawrence J. Knopf|
Title: Senior Vice President and